Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial Dermatology and Therapy February 2022;12(2):495-510

Date

02/01/2022

DOI

10.1007/s13555-021-00649-y

Scopus ID

2-s2.0-85123098014 (requires institutional sign-in at Scopus site)   24 Citations

Author List

Tha├ži D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB

Author

Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of Wisconsin